A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601
Recruiting
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced breast, colorectal, prostate, and endometrial cancer. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of California, Los Angeles (UCLA), Los Angeles, California +10 locations
Conditions: Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis
Register for Updates
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/20/2025
Locations: Accel Research, Birmingham, Alabama +126 locations
Conditions: Focal Epilepsy
Register for Updates
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
NCT02107989
Recruiting
Objectives: The overall study objective is to compare the sensitivities and specificities of morphometric analysis techniques using structural MRI images based on pre- and postsurgical localization of epileptic foci in patients undergoing presurgical evaluation for medically refractory epilepsy. To carry out these analyses, we aim to establish an age-stratified normative imaging database using healthy volunteers. Additional objectives are to identify abnormal networks in these patients using re... Read More
Gender:
ALL
Ages:
Between 8 years and 120 years
Trial Updated:
08/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Epilepsy
Register for Updates
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
NCT04530565
Recruiting
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/20/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +205 locations
Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Register for Updates
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT00001823
Recruiting
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
Register for Updates
Examination of Psychological and Physiological Pathways Linking Gratitude and Pain
NCT06317844
Recruiting
The goal of this clinical trial is to compare the effects of a brief gratitude intervention on individuals' psychological and physiological responses to acute pain. Furthermore, these associations will be examined in the context of genetic variations associated with both pain and psychological processes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Black Hills State University, Spearfish, South Dakota
Conditions: Acute Pain, Positive Thinking, Emotions
Register for Updates
VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older
NCT01132859
Recruiting
Background: - The Vaccine Research Center (VRC) is dedicated to understanding immune responses associated with prevention and treatment of infectious diseases. To study these immune responses, researchers need to collect specimens and images from individuals who have recently had a vaccination or recovered from an infection. These specimens and images are used to study different diseases and immune responses, and can be used to investigate ways to prevent or treat different medical conditions.... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Immunity, Mucosal, Immune System Processes, Blood Specimen Collection
Register for Updates
Prospective Breast Cancer Biospecimen Collection
NCT04074720
Recruiting
Tissue will be procured during a standard of care procedure the patient will already be scheduled to undergo. A one time blood draw will be performed at this time and an optional rectal swab for biome analysis may occur. Follow Up will only consist of chart review to determine date of recurrence, metastases, and/or death
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Breast Cancer, Invasive Breast Cancer, Carcinoma in Situ of the Breast
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/20/2025
Locations: Research Site, Athens, Alabama +908 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Men at High Genetic Risk for Prostate Cancer
NCT03805919
Recruiting
Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer. Objectives: To study men with specific genetic changes and determine who is at higher risk for getting prostate cancer. To study if certain genetic changes and family his... Read More
Gender:
MALE
Ages:
Between 30 years and 75 years
Trial Updated:
08/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms
Register for Updates
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
NCT03375307
Recruiting
This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: UC San Diego Health System - Encinitas, Encinitas, California +16 locations
Conditions: Advanced Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma
Register for Updates
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)
NCT03907475
Recruiting
This phase II trial studies the side effects of durvalumab when given together with chemotherapy in treating patients with solid tumors that have spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, capecitabine, carbop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Register for Updates